Jones v. Eli Lilly and Company

CourtDistrict Court, D. Maryland
DecidedApril 7, 2023
Docket8:20-cv-03564
StatusUnknown

This text of Jones v. Eli Lilly and Company (Jones v. Eli Lilly and Company) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jones v. Eli Lilly and Company, (D. Md. 2023).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND TANJANEKA JONES, * □

Plaintiff, * * vs. * Civil Action No. ADC-20-3564 fe ELI LILLY AND COMPANY, * * Defendant. * * OR CR OR OR GR deck koe HR ROOK ROR RR ROK OH ROR OR ok ok ok ok MEMORANDUM OPINION Defendant Eli Lilly and Company (“Defendant” or “Eli Lilly”) moves this Court for summary judgment on Plaintiff Tanjaneka Jones’s Third Amended Complaint. ECF Nos. 26, 48. After considering Defendant’s Motion and the responses thereto (ECF Nos. 48, 51, 52, 55), the Court finds that no hearing is necessary.! Loc.R. 105.6 (D.Md. 2021). For the reasons stated herein, Defendant’s motion for summary judgment is GRANTED, Factual Background Plaintiff is a Black woman who was hired as a senior sales representative at Eli Lilly in 2014. ECF No.. 48-2 at 29.2 She was originally assigned to the Baltimore District of Eli Lily’s Diabetes Business Unit where she was responsible for selling diabetes related products to physicians. /d. at 31-32. 51-52. Plaintiff received a base salary for her role and was also eligible for additional incentive compensation through Eli Lilly’s Premier Regards Program. /d. at 191-93;

1 On March 2, 2023, this case was referred to United States Magistrate Judge A. David Copperthite for all proceedings in accordance with 28 U.S.C. § 636 and Local Rules 301 and 302 (D.Md. 2021). ECF No. 59. 2 ECF No. 48-2 is a condensed copy of Plaintiff's deposition with four pages of deposition testimony printed to one page. Citations in this Opinion correspond to the deposition page number.

ECF No. 51-4. Plaintiff was originally supervised by Harald Mendoza, a White or Hispanic male. ECF No. 48-2 at 52, 55. In December of 2015, during Plaintiff s first full year at Eli Lilly, Mr. Mendoza issued Plaintiff a written warning for deficient performance. /d. at 56-57. Plaintiff was, in Mr. Mendoza’s opinion, failing to “consistently engage customers in a meaningful selling dialogue including using active listening skills, asking effective questions and demonstrating agile communications skills.” Jd. at 57. Given these issues, and others, he concluded that Plaintiff did not sufficiently meet her job expectations in 2015. Id. at 64-65. This was, however, the only disciplinary warning that Plaintiff received under Mr. Mendoza’s supervision, and she subsequently received a satisfactory performance rating in 2016. Jd. at 66. In July 2017, Andrea Gibson—a Black female—replaced Mr. Mendoza. /d. Under Ms. Gibson’s supervision, Plaintiff received a satisfactory performance rating in 2017. ECF No. 51-2 at 1. . As part of acompany realignment, Plaintiff was transferred to the Washington D.C. District of the Diabetes Business Unit in February 2018 where she was supervised by Jacquelyne Porter— a Black female. ECF No. 52 at 68-69.3 Shortly after her transfer, Plaintiff went out on maternity leave for three months. ECF No. 51-2 at 2. Although she briefly returned to work in June 2018, Plaintiff had to take medical leave in July 2018 for emergency neck surgery. /d. After nearly seven months of leave, Plaintiff returned to Eli Lilly on October 3, 2018. ECF No. 51-2 at 2. Once Plaintiff was back in the sales force, Ms. Porter noticed several performance deficiencies related to Plaintiff's value-based selling and pre-call planning. ECF No. 48-2 at 70. Based on these performance inadequacies, Ms. Porter rated Plaintiff's 2018 performance as “not sufficiently

3 ECF No, 52 is acondensed copy of Plaintiff's deposition with four pages of deposition testimony printed to one page. Citations in this Opinion correspond to the deposition page number.

meeting job expectations.” Jd. at 71. To spark improvement, Ms. Porter set up weekly check-in meetings with Plaintiff and advised her to “invest more time and practice in reviewing studies and data.” Id, at 70-71. In February 2019, Mark Hudson became the interim supervisor of Plaintiff's team. ECF No. 52 at 74. Prior to assuming this position, Mr. Hudson was the Mid-Atlantic sales trainer for Eli Lilly’s Diabetes Business Unit. Jd. at 75. In his training roll, Mr. Hudson accompanied Plaintiff on a field ride and trained her in value-based selling. /d. at 76, 126. In the months after assuming his new supervisory responsibilities, Mr. Hudson completed two additional field rides/visits with Plaintiff during which he—like Ms. Porter—noticed that Plaintiff's pre-call planning and value- based selling were inadequate. ECF No. 48-2 at 127-32. To correct these deficiencies, Mr. Hudson sent Plaintiff Eli Lilly training literature reenforcing the processes and procedures that sales representatives were expected to adhere to. Jd. Despite these efforts, Plaintiff's performance in these areas did not improve. Consequently, in May 2019, Mr. Hudson informed Plaintiff that she would be receiving a Performance Improvement Plan (“PIP”). Jd. at 140. Mr. Hudson was, however, ultimately replaced before the PIP was issued. Jd. On June 1, 2019, David Sun took over as the supervisor of Plaintiff's team. /d. at 77. During his first month on the job, Mr. Sun accompanied Plaintiff on a field ride and, like Ms. Porter and Mr. Hudson, observed gaps in Plaintiffs pre-call planning and customer facing abilities. ECF No. 48-3 at 1. Due to her “trend of unacceptable performance,” Plaintiff was issued a PIP by Mr. Hudson and Mr. Sun on June 28, 2019, Id This disciplinary action was taken despite Plaintiff exceeding her sales goals. ECF No. 26 at 4 8. The PIP specifically identified the following performance inadequacies: “[i]nadequate pre-call planning which has led to ineffective discussions with customers, lack of impact and influence during customer interactions”; “[I]ack of technical

knowledge of disease state”; “[i]nability to achieve consistently effective call progression and consistent sales results”; and “[l]ack of demonstrated team leadership at an S3 level.” Jd. Plaintiff was required to meet the following performance management goals to complete the PIP: adhere to value-based selling based on a structured pre-call plan; show sufficient technical knowledge on disease state with customers; conduct efficient dialogue with customers; and conduct monthly communications with her district. Jd at 3. Failure to meet these goals could “lead to further disciplinary action.” fd. After receiving the PIP, Plaintiff met regularly with Grace Faulkner, a member of the human resources office at Eli Lilly. ECF No. 48-2 at 89. In August 2019, Plaintiff reported to Ms. Faulkner that Mr. Sun was not accurately documenting her performance as he only documented interactions where she “had a slight error, or [] didn’t show something properly.” ECF No. 52 at 110. She also expressed that Mr. Sun was discrediting her accomplishments, such as her “strong sales record and client relationships.” ECF No, 51-2 at 4. Two months later, Plaintiff reported that Mr. Sun was discriminating against her on the basis of her sex and race. ECF No. 52 at 96. She alleged that Mr. Sun’s management style was abusive, demeaning, and upsetting. Id. at 97. She specifically recalled that Mr. Sun accused her of being “overemotional” and that he dismissed her questions but answered identical questions posed by her white colleagues. /d. at 96-98. Based on Plaintiffs allegations of discrimination, Ms. Faulkner immediately opened an investigation into Mr. Sun’s conduct. ECF No. 48-2 at 106. As part of this investigation, Ms. Faulkner interviewed five female members of Plaintiff’s team as well as Mr. Sun’s supervisor. ECF No. 48-5 at 58.4 While Plaintiff's teammates described Mr. Sun’s management style as

4 ECF No. 48-5 is a condensed copy of Ms. Faulkner’s deposition with four pages of deposition testimony printed to one page.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Coleman v. Maryland Court of Appeals
626 F.3d 187 (Fourth Circuit, 2010)
Dulaney v. Packaging Corp. of America
673 F.3d 323 (Fourth Circuit, 2012)
Lorraine Lettieri v. Equant Incorporated
478 F.3d 640 (Fourth Circuit, 2007)
Dorn B. Holland v. Washington Homes, Incorporated
487 F.3d 208 (Fourth Circuit, 2007)
Lightner v. City of Wilmington, NC
545 F.3d 260 (Fourth Circuit, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
Jones v. Eli Lilly and Company, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jones-v-eli-lilly-and-company-mdd-2023.